NSCLC patients who developed immune-related adverse events during immunotherapy showed longer overall survival and progression-free survival than patients who did not. A study of patients who received ...
An update to the ERNEST study found a survival benefit in ruxolitinib for the treatment of myelofibrosis in both the first and second line vs hydroxyurea. Patients with myelofibrosis (MF) face a lower ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results